CTKB reports Q1 2026 revenue of $44.1 million, up 6% year-over-year, as U.S. demand stabilizes.
Cytek Biosciences reaffirmed its full-year 2026 revenue outlook of $205 million to $212 million after reporting Q1 2026 revenue of $44.1 million. The figure marks a 6% increase from $41.5 million in Q1 2025, driven by a rebound in U.S. market conditions.
The company cited improved demand trends, contrasting with prior volatility. Analysts had anticipated modest growth, aligning with the reported figures. The guidance reaffirmation suggests confidence in sustained recovery.
No immediate market reaction was disclosed in the earnings call summary.